痛風市場 - 機会評価と予測

痛風の有病率は、主要7ヶ国市場の人口増加に伴い、AGR 1.18％と着実に増加しています。現在、主要7ヶ国市場における痛風の治療レジメンは、ほとんどが非ステロイド性抗炎症薬、コルチコステロイド、およびアロプリノールなどの安全性プロファイルが難しいULTに限られています。

この領域には、痛風に対する医師や患者の認識向上、重症痛風患者に対する治療法の改善など、いくつかのアンメットニーズが存在します。痛風の後期研究開発パイプラインは、慢性痛風治療用のULTの開発に重点を置いています。痛風人口の着実な増加と新規治療薬の市場参入により、予測期間を通じて大きな成長が見込まれます。

当レポートでは、主要7ヶ国（米国、欧州5ヶ国（フランス、ドイツ、イタリア、スペイン、英国））、日本の痛風市場について調査し、市場の概要とともに、2022年～2032年の市場予測、競合情勢などを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 病気の概要

• 痛風の概要
• 痛風のSWOT分析
• 痛風の分類

第4章 疫学

第5章 現在の治療選択肢

• 治療パラダイム
• 市販製品
• 製品プロファイル：NSAID
• 製品プロファイル：コルチコステロイド
• 製品プロファイル：Krystexxa（ペグロティカーゼ）
• 製品プロファイル：フェブキソスタット
• 製品プロファイル：尿再吸収剤
• 製品プロファイル：Colcrys（コルヒチン）
• 製品プロファイル：イラリス（カナキヌマブ）

第6章 アンメットニーズと機会

• 痛風のアンメットニーズ
• 医師と患者の痛風の認識
• 痛風治療の不遵守
• 痛風のより早期かつ正確な診断
• 治療困難な痛風の有効かつ安全な治療法

第7章 パイプラインの評価

第8章 研究開発戦略

• 痛風- 臨床試験（第II/III相）の概要
• 痛風の臨床試験デザインの動向
• 痛風における取引の動向

第9章 市場の見通し

• 痛風の売上予測
• 痛風の市場予測
• 市場促進要因と抑制要因

第10章 付録

第11章 お問い合わせ

Abstract

The prevalence of gout is increasing at a steady rate, in line with population growth in the 7MM, at an AGR of 1.18%.

Currently, the treatment regimen for gout in the 7MM is mostly limited to NSAIDs, corticosteroids, and ULTs with challenging safety profiles, such as allopurinol.

There are several unmet needs in this space, including the need for improved physician and patient awareness of gout and improved therapies for severe gout patients.

The gout late-stage R&D pipeline is focused on developing ULTs for chronic gout treatment.

Significant growth is expected throughout the forecast period as the gout population steadily increases and novel therapies enter the market.

Report deliverables include a Pdf report and Excel-based forecast model.

Forecast includes US, 5EU, and Japan [5EU (France, Germany, Italy, Spain, and the UK) were forecasted as one entity]

Forecasts cover 2022-2032.

Scope

• Overview of gout, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized gout therapeutics market revenue in 7MM (US, 5EU, and Japan), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the gout therapeutics market.
• Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for gout treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the 7MM gout therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the gout therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the gout therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Abbreviations
• 1.3. Related Reports

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Gout
• 3.2. Gout SWOT Analysis
• 3.3. Classification of Gout

4. Epidemiology

• 4.1. Diagnosed Prevalent Cases of Gout
• 4.2. Age-Specific Trends in Diagnosed Prevalent Cases of Gout
• 4.3. Sex-Specific Diagnosed Prevalent Cases of Gout
• 4.4. Sources and Methodology for Gout Prevalence
• 4.5. Sources and Methodology for Gout

5. Current Treatment Options

• 5.1. Treatment Paradigm
• 5.2. Marketed Products
• 5.3. Product Profile: NSAIDs
• 5.4. Product Profile: Corticosteroids
• 5.5. Product Profile: Krystexxa (Pegloticase)
• 5.6. Product Profile: Febuxostat
• 5.7. Product Profile: Urine Reabsorption Agents
• 5.8. Product Profile: Colcrys (colchicine)
• 5.9. Product Profile: Ilaris (canakinumab)

6. Unmet Needs and Opportunities

• 6.1. Unmet Needs in Gout
• 6.2. Physician and Patient Awareness of Gout
• 6.3. Noncompliance to Gout Therapies
• 6.4. Earlier and More Accurate Diagnosis of Gout
• 6.5. Efficacious and Safe Treatment of Difficult-to-Treat Gout

7. Pipeline Assessment

• 7.1. Gout Pipeline Overview
• 7.2. Leading Pipeline Agents
• 7.3. Product Profile: Dapansutrile
• 7.4. Product Profile: Urece (dotinurad) - pediatric use
• 7.5. Product Profile: Pegadricase
• 7.6. Product Profile: Tigulixostat
• 7.7. Product Profile: ABP-671
• 7.8. Product Profile: SAP-001
• 7.9. Product Profile: Sodium Bicarbonate

8. R&D Strategies

• 8.1. Gout - Clinical Trials (Phase II/III) Overview
• 8.2. Trends in Clinical Trial Design in Gout
• 8.3. Trends in Deal-Making in Gout

9. Market Outlook

• 9.1. Gout Sales Forecast
• 9.2. Gout Market Forecast
• 9.3. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research - KOL Information
• 10.2. About the Authors

11. Contact Us